Losing hair is one of the most noticeable and upsetting side effect for cancer patients going through chemotherapy. But a new process, called cold cap therapy, is helping more of these patients keep their hair.

One of the biggest obstacles to eradicating malaria is a dormant form of the parasite that lurks in the livers of some patients. This dormant form is resistant to most antimalarial drugs and can reawaken months or years later, causing disease relapse.

The Children’s Heart Foundation and the American Heart Association announced their latest collaborative investment in research to better understand and treat congenital heart defects (CHDs), the number one birth defect in the United States. This is the fourth round of their co-funded Congenital Heart Defect Research Awards program and represents a $826,600 investment in seven research programs from around the country. The program will ultimately fund more than $22 million in CHD-specific research through 2021.

For years, researchers have been trying to figure out better ways to find out if a person has cancer and to find it early when it’s most curable. They want a test that’s easier on patients and faster for doctors. One idea that’s gaining ground is called a liquid biopsy. A biopsy is a sample of tissue or cells taken from almost any part of the body and sent to a lab to check for cancer. The liquid in this case is your blood. The concept is that your doctor may one day be able to use a small sample of your blood to screen for cancer, before you have any symptoms.

The Federal Trade Commission has approved an application by Fresenius Medical Care AG & Co. KGaA to establish a new outpatient hemodialysis clinic in Wyoming, Michigan at a location previously divested by Fresenius.

The U.S. Food and Drug Administration today expanded the approved use of Nucala (mepolizumab) to treat adult patients with eosinophilic granulomatosis with polyangiitis (EGPA), a rare autoimmune disease that causes vasculitis, an inflammation in the wall of blood vessels of the body. This new indication provides the first FDA-approved therapy specifically to treat EGPA.